SIRS-Lab with its diagnostic portfolio! VYOO Sepsis Test is a multiplex pcr detection kit to identifiy bacteria and fungi in whole blood! LOOXSTER sample preparation kit concentrates bacterial and fungal DNA! With expert knowledge in molecular diagnostic, critical care medicine, microbiology, assay design and gene expression service!
Missing: SIRS-Lab's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: SIRS-Lab's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
SIRS-Lab has filed 1 patent.
Molecular biology, DNA, Transcription factors, DNA replication, Biotechnology
Molecular biology, DNA, Transcription factors, DNA replication, Biotechnology
SIRS-Lab Frequently Asked Questions (FAQ)
When was SIRS-Lab founded?
SIRS-Lab was founded in 2000.
What is SIRS-Lab's latest funding round?
SIRS-Lab's latest funding round is Other Investors.
Who are the investors of SIRS-Lab?
Investors of SIRS-Lab include Venture Capital Fund of New England, Affentranger Associates, bm-t beteiligungsmanagement thuringen and KfW.
Who are SIRS-Lab's competitors?
Competitors of SIRS-Lab include BioGX, OpGen, HTG Molecular Diagnostics, WaferGen Bio-systems, CareDx and 13 more.
Compare SIRS-Lab to Competitors
The KRMS aims to provide their organization with the tools needed to keep the key ingredients of research at their scientists' fingertips. Using the KRMS, researchers as well as stockroom, purchasing and EH&S personnel readily find, request, receive and track all chemical products. Inventory Management Reagent & Chemical Management for Pharma, BioTech, Manufacturers and Integrators (ELN, ERP, LIMS) Genome mining, sequence profiling and optimization Enhance their bioinformatics discovery program with SeqR. SeqR applies machine learning to public and sequence data to generate models with powerful sequence profiling abilities well suited to genome mining, sequence optimization, and SAR analysis.
Entegrion is a life sciences development company specializing in technologies that support preserve the function of the human vascular system. The company's technologies are designed to overcome limitations in temperature, storage, safety, and availability of blood-derived products while improving functionality. The company was founded in 2002 and is based in Durham, North Carolina.
BioGX, Inc. aims to provide custom assay design and development services and also is currently developing and selling tests for molecular based detection across numerous applications, including, but not limited to: detection of bacteria or viruses in food or the environment, water quality testing (for microbial or viral contamination), testing of foods, plants, and animals, and diverse other applications. Working with the Customer Specific Reagent (CSR) program of Cepheid, Inc., the company also provide conversion of existing assays to a convenient bead format utilizing Cepheid's technology, and custom development of customer-specific applications on Cepheid's platforms. The company provide development services and CSR bead manufacturing support across multiple instrument platforms and detection technologies.
Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
Bioventix is a biotechnology company specializing in the development of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing.
CAPE Technologies, of South Portland created a practical immunoassay-based test kits for dioxin and dioxin-like PCBs. The kits provide near real time analysis in a simple field lab, at lower cost, with less equipment, and with fewer people, than conventional methods. CAPE's dioxin kit is the only rapid dioxin screening method accepted by the U.S. Environmental Protection Agency (EPA) for solid waste analysis. A third kit is also available for rapid field analysis of total PCBs. CAPE's kits are marketed by distributors in Australia, Japan, Italy, Taiwan, China, and Finland, and directly through its web site to the rest of the world. CAPE Technologies maintains local ties with the University of New England, the University of Southern Maine, and the University of Maine at Orono. Dr. Robert Harrison of Cape Elizabeth is co-founder and president.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.